Study

EORTC-2427-BTG

Vorasidenib as maintenance treatment after first-line chemoradiotherapy in IDH-mutant grade 2 or 3 astrocytoma: a placebo-controlled, triple-blind, randomized phase III study (VIGOR)

Study documentation Back to result

Trial Status

Recruiting

Dates

Date of activation: 16-Jan-2026

Data management at EORTC

Yes

Design

Phase 3
Randomized open label

Targeted Sample size

EORTC Groups: 284 - All Groups: 468

Treatment

Drug
Vorasidenib, Blind trial medication-2427

Study Staff

  • Matthias Preusser (Study Coordinator), Medical University of Vienna, University Hospital AKH Vienna, Vienna
  • Marjolein Geurts (Y-ECI Coordinator), Erasmus MC, Rotterdam
  • Christopher Doty (Project Manager), EORTC Headquarters, Brussels
  • Daniel Portik (Clinical Research Physician), EORTC Headquarters, Brussels
  • Daniel Portik (Clinical Research Physician), EORTC Headquarters, Brussels
  • Jose Silva (Clinical Research Physician), EORTC Headquarters, Brussels
  • Caroline Quoilin (Clinical Scientist), EORTC Headquarters, Brussels
  • Fanny Hoogstoel (Statistician), EORTC Headquarters, Brussels
  • Murielle Mauer (Statistician), EORTC Headquarters, Brussels
  • Nitish Jha (Statistical Analyst), EORTC Headquarters, Brussels
  • Fanny Grillet (TR Scientist), EORTC Headquarters, Brussels
  • David Ndah Aki (Clinical Operations Manager), EORTC Headquarters, Brussels
  • Sophie Roulet (Junior Clinical Operations Manager), EORTC Headquarters, Brussels
  • Konstantina Tsechilidou (Data Manager), EORTC Headquarters, Brussels
  • Lore Meelberghs (Study Designer), EORTC Headquarters, Brussels
  • Lien Styns (Study Designer), EORTC Headquarters, Brussels
  • Nabila Sebti (Imaging DM), EORTC Headquarters, Brussels
  • Tim Verbiest (Clinical Data Expert), EORTC Headquarters, Brussels
  • Sara Meloen (Pharmacovigilance Manager), EORTC Headquarters, Brussels
  • Eliza Starczewska (Regulatory Affairs Manager), EORTC Headquarters, Brussels
  • Anja Mestnik (Junior RAM), EORTC Headquarters, Brussels
  • Luminita Copaceanu (Lead CRA), EORTC Headquarters, Brussels
  • Miguel Remis (Lead CRA), EORTC Headquarters, Brussels
  • Stefanos Soraruff (Clinical Operations Assistant), EORTC Headquarters, Brussels
  • Anne Esser (QoL Specialist), EORTC Headquarters, Brussels
  • Lotte van der Weijst (QoL Specialist), EORTC Headquarters, Brussels
  • Beatrice Fournier (Unblinded Clinical Scientist), EORTC Headquarters, Brussels
  • Carla Sureda (Unblinded COM), EORTC Headquarters, Brussels
  • Sandrine Marreaud (Unblinded CRP), EORTC Headquarters, Brussels
  • Myrto Moutafi (Unblinded CRP), EORTC Headquarters, Brussels
  • Myrto Moutafi (Unblinded CRP), EORTC Headquarters, Brussels
  • Olga Basova (Unblinded statistician), EORTC Headquarters, Brussels

Type of cancer

  • Brain

Participating groups

  • EORTC Brain Tumor Group
  • Cooperative Trials Group for Neuro-Oncology
  • Canadian Cancer Trials Group

Recruiting centers

  • A.O Landeskrankenhaus - Innsbruck Universitaetsklinik (Innsbruck, Austria)
  • APHP Sorbonne Univ - Hopital la Pitie-Salpetriere (PARIS, France)
  • Academisch Ziekenhuis Maastricht (Maastricht, Netherlands)
  • Amsterdam UMC stichting - locatie VUMC (Amsterdam, Netherlands)
  • Azienda Ospedaliera Città della Salute e della Scienza di Torino - Ospedale San Giovanni - Dipartimento Neuroscienze (Torino, Italy)
  • CHU Lyon - Hopital neurologique Pierre Wertheimer (BRON CEDEX, France)
  • CHU de Bordeaux - Groupe Hospitalier Saint-Andre - Hopital Saint-Andre (BORDEAUX CEDEX, France)
  • CHU de Toulouse - Institut Claudius Regaud - IUCT oncopole (TOULOUSE, France)
  • Erasmus MC (Rotterdam, Netherlands)
  • Hopital de La Timone (APHM) (MARSEILLE, France)
  • Hospital De La Santa Creu I Sant Pau (Barcelona, Spain)
  • Hospital Universitari Vall d’Hebron -Vall d'Hebron Institut Oncologia (Barcelona, Spain)
  • Hospital Universitario 12 De Octubre (Madrid, Spain)
  • IRCCS - Istituto Oncologico Veneto (Padova, Italy)
  • IRCCS--Ospedale Bellaria-Bologna (Bologna, Italy)
  • Kepler University Hospital - Neuromed campus (Linz, Austria)
  • Masaryk Memorial Cancer Institute (Brno, Czech Republic)
  • Medical University of Vienna, University Hospital AKH Vienna (Vienna, Austria)
  • U.Z. Leuven - Campus Gasthuisberg (Leuven, Belgium)
  • UniversitaetsKlinikum Heidelberg - Head Hospital (Heidelberg, Germany)
  • UniversitaetsMedizin Mannheim (Mannheim, Germany)
  • UniversitaetsSpital Zurich - Neurology Clinic (Zurich, Switzerland)
  • Universitaetsklinikum Bonn (Bonn, Germany)
  • Universitaetsklinikum Regensburg (Regensburg, Germany)
  • Universitaetsspital Basel (Basel, Switzerland)
  • Universitair Ziekenhuis Brussel (Brussels, Belgium)
  • Universitair Ziekenhuis Gent (Gent, Belgium)
  • University Hospital Frankfurt- Klinik für Neurologie Funktionsbereich Neuroonkologie (Frankfurt Am Main, Germany)

Centers to be activated

  • Alfred Hospital (Prahran, Australia)
  • Arthur J.E. Child Comprehensive Cancer Centre (former Tom Baker Cancer Center) (Calgary, Canada)
  • Austin Health - Austin hospital (Heidelberg VIC, Australia)
  • CHU de Quebec-Hopital l'Enfant-Jesus (HEJ) (Quebec, Canada)
  • CHUM - Centre hospitalier de l'Université de Montréal (Montreal, Canada)
  • Cancercare Manitoba (Winnipeg, Canada)
  • Centre Hospitalier Universitaire de Sherbrooke-Fleurimont (Sherbrooke, Canada)
  • Chris O'Brien Lifehouse (Camperdown NSW , Australia)
  • Chuq-Pavillon Hotel-Dieu De Quebec (Quebec, Canada)
  • Clatterbridge Cancer Center - Wirral (Wirral, United Kingdom)
  • Flinders Medical Centre (Bedford Park, Australia)
  • Hamilton Health Sciences, Juravinski Cancer Centre (Hamilton, Canada)
  • Hopital Du Sacre-Coeur De Montreal (Montreal, Quebec, Canada)
  • Kingston Health Sciences Centre (Kingston, Canada)
  • Liverpool Hospital (Liverpool, Australia)
  • London Regional Cancer Center (London, Canada)
  • Odette Cancer Centre - Sunnybrook Health Sciences Centre (Toronto (Ontario), Canada)
  • Ospedale Fatebenefratelli Isola Tiberina Gemelli Isola (Roma, Italy)
  • Ottawa Hospital Research Institute (Ottawa, Canada)
  • Peter Maccallum Cancer Institute (Melbourne, Australia)
  • QEII Health Sciences Centre-Capital District Health Authority (Halifax, Canada)
  • Royal Hobart Hospital (Hobart, Australia)
  • Royal Marsden Hospital - Sutton, Surrey (Surrey, United Kingdom)
  • Royal North Shore Hospital (St Leonards, Australia)
  • Sir Charles Gairdner Hospital (Nedlands, Australia)
  • The Christie NHS Foundation Trust (Manchester, United Kingdom)
  • UHB-Queen Elizabeth Medical Centre (Birmingham, United Kingdom)
  • University Health Network / Princess Margaret Cancer Center (Toronto, Canada)
  • University of Alberta - Cross Cancer Institute (Edmonton, Canada)

Protocol summary

http://clinicaltrials.gov/study/NCT06809322

NCT number

NCT06809322